View Item 

Show simple item record

Patient‐Reported Outcomes and Early Discontinuation in Aromatase Inhibitor‐Treated Postmenopausal Women With Early Stage Breast Cancer

dc.contributor.authorKadakia, Kunal C.
dc.contributor.authorSnyder, Claire F.
dc.contributor.authorKidwell, Kelley M.
dc.contributor.authorSeewald, Nicholas J.
dc.contributor.authorFlockhart, David A.
dc.contributor.authorSkaar, Todd C.
dc.contributor.authorDesta, Zereunesay
dc.contributor.authorRae, James M.
dc.contributor.authorOtte, Julie L.
dc.contributor.authorCarpenter, Janet S.
dc.contributor.authorStorniolo, Anna M.
dc.contributor.authorHayes, Daniel F.
dc.contributor.authorStearns, Vered
dc.contributor.authorHenry, N. Lynn
dc.date.accessioned2017-12-15T16:47:56Z
dc.date.available2017-12-15T16:47:56Z
dc.date.issued2016-05
dc.identifier.citationKadakia, Kunal C.; Snyder, Claire F.; Kidwell, Kelley M.; Seewald, Nicholas J.; Flockhart, David A.; Skaar, Todd C.; Desta, Zereunesay; Rae, James M.; Otte, Julie L.; Carpenter, Janet S.; Storniolo, Anna M.; Hayes, Daniel F.; Stearns, Vered; Henry, N. Lynn (2016). "Patient‐Reported Outcomes and Early Discontinuation in Aromatase Inhibitor‐Treated Postmenopausal Women With Early Stage Breast Cancer." The Oncologist 21(5): 539-546.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139968
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherEarly discontinuation
dc.subject.otherQuality of life
dc.subject.otherAromatase inhibitors
dc.subject.otherPatient‐reported outcomes
dc.titlePatient‐Reported Outcomes and Early Discontinuation in Aromatase Inhibitor‐Treated Postmenopausal Women With Early Stage Breast Cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
dc.contributor.affiliationumDepartment of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA
dc.contributor.affiliationotherIndiana University School of Nursing, Indianapolis, Indiana, USA
dc.contributor.affiliationotherBreast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
dc.contributor.affiliationotherDivision of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
dc.contributor.affiliationotherDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
dc.contributor.affiliationotherMelvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139968/1/onco0539-sup-0002.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139968/2/onco0539.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139968/3/onco0539-sup-0001.pdf
dc.identifier.doi10.1634/theoncologist.2015-0349
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceJJ Mao, C Stricker, D Bruner. Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivors. Cancer. 2009; 115: 3631 – 3639.
dc.identifier.citedreferenceEarly Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient‐level meta‐analysis of the randomised trials. Lancet. 2015; 386: 1341 – 1352.
dc.identifier.citedreferenceL Fallowfield, D Cella, J Cuzick. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol. 2004; 22: 4261 – 4271.
dc.identifier.citedreferenceLJ Fallowfield, JM Bliss, LS Porter. Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006; 24: 910 – 917.
dc.identifier.citedreferenceTJ Whelan, PE Goss, JN Ingle. Assessment of quality of life in MA.17: A randomized, placebo‐controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005; 23: 6931 – 6940.
dc.identifier.citedreferenceCC Murphy, LK Bartholomew, MY Carpentier. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res Treat. 2012; 134: 459 – 478.
dc.identifier.citedreferenceNL Henry, F Azzouz, Z Desta. Predictors of aromatase inhibitor discontinuation as a result of treatment‐emergent symptoms in early‐stage breast cancer. J Clin Oncol. 2012; 30: 936 – 942.
dc.identifier.citedreferenceKD Crew, H Greenlee, J Capodice. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early‐stage breast cancer. J Clin Oncol. 2007; 25: 3877 – 3883.
dc.identifier.citedreferenceA Kemp, DB Preen, C Saunders. Early discontinuation of endocrine therapy for breast cancer: Who is at risk in clinical practice?. Springerplus. 2014; 3: 282.
dc.identifier.citedreferencePE Goss, JN Ingle, KI Pritchard. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27–a randomized controlled phase III trial. J Clin Oncol. 2013; 31: 1398 – 1404.
dc.identifier.citedreferenceNL Henry, HP Chan, J Dantzer. Aromatase inhibitor‐induced modulation of breast density: Clinical and genetic effects. Br J Cancer. 2013; 109: 2331 – 2339.
dc.identifier.citedreferenceAS Pickard, CT Wilke, HW Lin. Health utilities using the EQ‐5D in studies of cancer. Pharmacoeconomics. 2007; 25: 365 – 384.
dc.identifier.citedreferenceAS Pickard, MP Neary, D Cella. Estimation of minimally important differences in EQ‐5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007; 5: 70.
dc.identifier.citedreferenceJS Carpenter, MA Andrykowski, J Wilson. Psychometrics for two short forms of the Center for Epidemiologic Studies‐Depression Scale. Issues Ment Health Nurs. 1998; 19: 481 – 494.
dc.identifier.citedreferenceL Stafford, F Judd, P Gibson. Comparison of the hospital anxiety and depression scale and the center for epidemiological studies depression scale for detecting depression in women with breast or gynecologic cancer. Gen Hosp Psychiatry. 2014; 36: 74 – 80.
dc.identifier.citedreferencePA Ganz, R Day, JE Ware Jr. Base‐line quality‐of‐life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst. 1995; 87: 1372 – 1382.
dc.identifier.citedreferenceRJ Santen, L Demers, S Ohorodnik. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids. 2007; 72: 666 – 671.
dc.identifier.citedreferenceZ Desta, Y Kreutz, AT Nguyen. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther. 2011; 90: 693 – 700.
dc.identifier.citedreferenceD Cella, SR Land, CH Chang. Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P‐1): Psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat. 2008; 109: 515 – 526.
dc.identifier.citedreferenceHJ Burstein, S Temin, H Anderson. Adjuvant endocrine therapy for women with hormone receptor‐positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32: 2255 – 2269.
dc.identifier.citedreferenceK Chim, SX Xie, CT Stricker. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer. 2013; 13: 401.
dc.identifier.citedreferenceNL Henry, A Conlon, KM Kidwell. Effect of estrogen depletion on pain sensitivity in aromatase inhibitor‐treated women with early‐stage breast cancer. J Pain. 2014; 15: 468 – 475.
dc.identifier.citedreferenceJ Bauml, L Chen, J Chen. Arthralgia among women taking aromatase inhibitors: Is there a shared inflammatory mechanism with co‐morbid fatigue and insomnia?. Breast Cancer Res. 2015; 17: 89.
dc.identifier.citedreferenceDL Hershman, JM Unger, KD Crew. Randomized multicenter placebo‐controlled trial of omega‐3 fatty acids for the control of aromatase inhibitor‐induced musculoskeletal pain: SWOG S0927. J Clin Oncol. 2015; 33: 1910 – 1917.
dc.identifier.citedreferenceP Hadji, M Blettner, N Harbeck. The Patient’s Anastrozole Compliance to Therapy (PACT) Program: A randomized, in‐practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013; 24: 1505 – 1512.
dc.identifier.citedreferenceP Neven, C Markopoulos, M Tanner. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First‐year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast. 2014; 23: 393 – 399.
dc.identifier.citedreferenceKD Yu, Y Zhou, GY Liu. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat. 2012; 134: 307 – 313.
dc.identifier.citedreferenceR Day, PA Ganz, JP Costantino. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project’s Breast Cancer Prevention (P‐1) Randomized Study. J Natl Cancer Inst. 2001; 93: 1615 – 1623.
dc.identifier.citedreferenceS Ohsumi, K Shimozuma, Y Ohashi. Health‐related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1‐4 years: N‐SAS BC 03. Breast Cancer Res Treat. 2011; 127: 143 – 152.
dc.identifier.citedreferenceH Takei, S Ohsumi, K Shimozuma. Health‐related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N‐SAS BC 04). Breast Cancer Res Treat. 2012; 133: 227 – 236.
dc.identifier.citedreferenceN Taira, H Iwata, Y Hasegawa. Health‐related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. Breast Cancer Res Treat. 2014; 145: 155 – 164.
dc.identifier.citedreferenceD Cella, L Fallowfield, P Barker. Quality of life of postmenopausal women in the ATAC (“Arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006; 100: 273 – 284.
dc.identifier.citedreferenceHB Muss, D Tu, JN Ingle. Efficacy, toxicity, and quality of life in older women with early‐stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008; 26: 1956 – 1964.
dc.identifier.citedreferenceSE Jones, J Cantrell, S Vukelja. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol. 2007; 25: 4765 – 4771.
dc.identifier.citedreferencePA Ganz. Assessing the quality and value of quality‐of‐life measurement in breast cancer clinical trials. J Natl Cancer Inst. 2011; 103: 196 – 199.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0539-sup-0002.pdf
Size:
185.9KB
Format:
PDF
View/Open
Name:
onco0539.pdf
Size:
1.071MB
Format:
PDF
View/Open
Name:
onco0539-sup-0001.pdf
Size:
157.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.